Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 363 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... December 18, 2019 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer August 2, 2019 Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 Load more HOT NEWS FDA Approvals Bring New Options for Older Patients with AML Why people and culture matter in research Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... For Some Kids with Brain Cancer, Targeted Therapy is Better than...
